Knockdown of Ski decreases osteosarcoma cell proliferation and migration by suppressing the PI3K/Akt signaling

Xin Zhao1, Yuying Fang2, Xingwen Wang3

  • 1Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Insights

Ski protein is upregulated in osteosarcoma (OS) and drives cancer cell proliferation and migration. Inhibiting Ski may offer a new therapeutic strategy for treating OS by blocking the PI3K/Akt pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ski is an evolutionarily conserved protein implicated in various cancers.
  • Limited research exists on Ski's role in osteosarcoma (OS) development.

Purpose of the Study:

  • To investigate the differential expression of Ski in OS.
  • To elucidate the functional role of Ski in OS cell proliferation and migration.
  • To explore the underlying molecular mechanisms, including the PI3K/Akt signaling pathway.

Main Methods:

  • Differential expression analysis of Ski in OS tissues and cell lines.
  • Ski knockdown using small interfering RNA (siRNA).
  • Cell proliferation assays (CCK8, EdU staining, cell cycle analysis).
  • Cell migration assay (wound healing).
  • Western blot analysis for PI3K/Akt pathway proteins.

Main Results:

  • Ski expression was significantly upregulated in OS tissues and cell lines compared to normal tissues and cells.
  • Ski knockdown markedly inhibited OS cell proliferation and migration.
  • Ski knockdown led to a prominent decrease in the phosphorylation of PI3K and Akt proteins.

Conclusions:

  • Ski acts as a tumor promoter in osteosarcoma by enhancing cell proliferation and migration.
  • Ski's oncogenic function in OS is mediated through the PI3K/Akt signaling pathway.
  • Ski represents a potential therapeutic target for osteosarcoma treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K